Revance Therapeutics, Inc. — Net Income by Fiscal Year
22 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/88f7b582-f5fb-4d7a-b3c0-189c831fc673/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-324.0M | 2023-01-01 – 2023-12-31 | evidence 0001479290-24-000038 |
| FY 2022 | $-356.4M | 2022-01-01 – 2022-12-31 | evidence 0001479290-23-000028 |
| FY 2021 | $-281.3M | 2021-01-01 – 2021-12-31 | evidence 0001479290-22-000034 |
| FY 2020 | $-282.1M | 2020-01-01 – 2020-12-31 | evidence 0001479290-21-000057 |
| FY 2019 | $-159.4M | 2019-01-01 – 2019-12-31 | evidence 0001479290-20-000042 |
| FY 2018 | $-142.6M | 2018-01-01 – 2018-12-31 | evidence 0001479290-19-000030 |
| FY 2017 | $-120.6M | 2017-01-01 – 2017-12-31 | evidence 0001479290-18-000038 |
| FY 2016 | $-89.3M | 2016-01-01 – 2016-12-31 | evidence 0001479290-17-000013 |
| FY 2015 | $-73.5M | 2015-01-01 – 2015-12-31 | evidence 0001479290-16-000031 |
| FY 2014 | $-62.9M | 2014-01-01 – 2014-12-31 | evidence 0001628280-15-001461 |
| FY 2013 | $-292.2M | 1999-08-10 – 2014-03-31 | evidence 0001193125-14-199234 |
| FY 2012 | $-32.2M | 2012-01-01 – 2012-12-31 | evidence 0001628280-15-006314 |
| FY 2011 | $-44.9M | 2011-01-01 – 2011-12-31 | evidence 0001193125-14-199234 |
| FY 2010 | $-29.2M | 2010-01-01 – 2010-12-31 | evidence 0001193125-14-199234 |
| FY 2009 | $-24.1M | 2009-01-01 – 2009-12-31 | evidence 0001193125-14-199234 |
| FY 2008 | $-22.0M | 2008-01-01 – 2008-12-31 | evidence 0001193125-14-199234 |
| FY 2007 | $-20.0M | 2007-01-01 – 2007-12-31 | evidence 0001193125-14-199234 |
| FY 2006 | $-9.4M | 2006-01-01 – 2006-12-31 | evidence 0001193125-14-199234 |
| FY 2005 | $-5.0M | 2005-01-01 – 2005-12-31 | evidence 0001193125-14-199234 |
| FY 2004 | $-2.5M | 2004-01-01 – 2004-12-31 | evidence 0001193125-14-199234 |
| FY 2003 | $-1.2M | 2003-01-01 – 2003-12-31 | evidence 0001193125-14-199234 |
| FY 2002 | $-1.9M | 2002-01-01 – 2002-12-31 | evidence 0001193125-14-199234 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Revance Therapeutics, Inc. — all facts · Revenue · Operating Income